Paroxysmal kinesigenic dyskinesia
Authors:
- Xiao-Jun HuangXHXiao-Jun Huang
- Tian WangTWTian Wang
- Jun-Ling WangJWJun-Ling Wang
- Xiao-Li LiuXLXiao-Li Liu
- Xiang-Qian CheXCXiang-Qian Che
- Jin LiJLJin Li
- Xiao MaoXMXiao Mao
- Mei ZhangMZMei Zhang
- Guang-Hui BiGBGuang-Hui Bi
- Li WuLWLi Wu
- Yu ZhangYZYu Zhang
- Jing-Yi WangJWJing-Yi Wang
- 3 November 2015
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 85 (18) , 1546-1553
Abstract
Objective: We aimed to investigate the clinical and genetic features of paroxysmal kinesigenic dyskinesia (PKD) in a large population and to analyze the genotype–phenotype correlation of PKD. Methods: We analyzed clinical manifestations and conducted PRRT2 screening in 110 patients with PKD. Clinical data were compared between 91 probands with and without PRRT2 mutations. Results: Among the enrolled participants (45 from 26 families, 65 sporadic cases), 8 PRRT2 mutations were detected in 20 PKD families (76.9%) and 14 sporadic cases (21.5%), accounting for 37.4% (34/91) of the study population. Five mutations (c.649dupC, c.649delC, c.487C>T, c.573dupT, c.796C>T) were already reported, while 3 mutations (c.787C>T, c.797G>A, c.931C>T) were undocumented. A patient harboring a homozygous c.931C>T mutation was shown to have inherited the mutation via uniparental disomy. Compared with non-PRRT2 mutation carriers, the PRRT2 mutation carriers were younger at onset, experienced longer attacks, and tended to present with complicated PKD, combined phenotypes of dystonia and chorea, and a positive family history. A good response was shown in 98.4% of the patients prescribed with carbamazepine. Conclusions: PRRT2 mutations are common in patients with PKD and are significantly associated with an earlier age at onset, longer duration of attacks, a complicated form of PKD, combined phenotypes of dystonia and chorea, and a tendency for a family history of PKD. A patient with uniparental disomy resulting in a homozygous c.931C>T mutation is identified in the present study. Carbamazepine is the first-choice drug for patients with PKD, but an individualized treatment regimen should be developed.Keywords
This publication has 38 references indexed in Scilit:
- Novel PRRT2 mutations in paroxysmal dyskinesia patients with variant inheritance and phenotypesGenes, Brain and Behavior, 2012
- PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraineNeurology, 2012
- PRRT2 gene mutationsNeurology, 2012
- PRRT2 links infantile convulsions and paroxysmal dyskinesia with migraineNeurology, 2012
- PRRT2 Mutations in Paroxysmal Kinesigenic Dyskinesia with Infantile Convulsions in a Taiwanese CohortPLOS ONE, 2012
- Genetic and phenotypic heterogeneity in sporadic and familial forms of paroxysmal dyskinesiaJournal of Neurology, 2012
- Mutations in the Gene PRRT2 Cause Paroxysmal Kinesigenic Dyskinesia with Infantile ConvulsionsCell Reports, 2012
- Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosisJournal of Medical Genetics, 2011
- Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesiasBrain, 2011
- Recombinant versus Urinary Follicle-Stimulating Hormone in the Low-Dose Regimen in Anovulatory Patients with Polycystic Ovary Syndrome: A Safer and More Effective TreatmentHormone Research in Paediatrics, 2001